Structure of human dCK suggests strategies to improve anticancer and antiviral therapy

Nature Structural Biology

Volumn 10, Issue 7, 2003, Pages 513-519

  Sabini, Elisabetta ^a   Ort, Stephan ^b   Monnerjahn, Christian ^b   Konrad, Manfred ^b   Lavie, Arnon ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DEOXYADENOSINE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DEOXYGUANOSINE; DEOXYRIBONUCLEOSIDE; GEMCITABINE; NUCLEOSIDE ANALOG; PRODRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENE THERAPY; HYDROGEN BOND; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; SUICIDE GENE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BIOTRANSFORMATION; DEOXYCYTIDINE KINASE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY;

EID: 0038419639     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsb942     Document Type: Article

References (37)

1. Hapke, D.M., Stegmann, A.P. & Mitchell, B.S. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. 56, 2343-2347 (1996).
2. Owens, J.K., Shewach, D.S., Ullman, B. & Mitchell, B.S. Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. 52, 2389-2393 (1992).
3. Ruiz van Haperen, V.W. et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res, 54, 4138-4143 (1994),
4. Stegmann, A.P., Honders, W.H., Willemze, R., Ruiz van Haperen, V.W. & Landegent, J.E. Transfection of wild-type deoxycytidine kinase (dCK) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity, Blood 85, 1188-1194 (1995).
5. Blackstock, A.W. et al. Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin. Cancer Res. 7, 3263-3268 (2001).
6. Ostermann, N. et al. Insights into the phosphoryltransfer mechanism of human thymidylate kinase gained from crystal structures of enzyme complexes along the reaction coordinate. Structure 8, 629-642 (2000).
7. Bergman, A., Pinedo, H. & Peters, G. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist. Updat. 5, 19-33 (2002).
8. Johansson, K. et al. Structural basis for substrate specificities of cellular deoxyribonucleoside kinases. Nat. Struct. Biol. 8, 616-620 (2001).
9. Hendrickson, W.A. & Ogata, C.M. Phase determination from multiwavelength anomalous diffraction measurements. Methods Enzymol. 276, 494-523 (1997).
10. Ramachandran, G.N., Ramakrishnan, C. & Sasisekharan, V. Stereochemistry of polypeptide chain configuration. J. Mol. Biol. 33, 491-497 (1963).
11. Knecht, W. et al. A few amino acid substitutions can convert deoxyribonucleoside kinase specificity from pyrimidines to purines. EMBO J. 21, 1873-1880 (2002).
12. Herrstrom Sjoberg, A., Wang, L. & Eriksson, S. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. Mol. Pharmacol. 53, 270-273 (1998).
13. Usova, E.V. & Eriksson, S. Identification of residues involved in the substrate specificity of human and murine dCK. Biochem. Pharmacol. 64, 1559-1567 (2002).
14. White, J.C. & Capizzi, R.L. A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-β-o-arabinofuranosylcytosine phosphorylation in human leukemia cells. Cancer Res. 51, 2559-2565 (1991).
15. Shewach, D.S., Reynolds, K.K. & Hertel, L. Nucleotide specificity of human deoxycytidine kinase. Mol. Pharmacol. 42, 518-524 (1992).
16. Hughes, T.L., Hahn, T.M., Reynolds, K.K. & Shewach, D.S. Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate. Biochemistry 36, 7540-7547 (1997).
17. Eriksson, S., Munch-Petersen, B., Johansson, K. & Eklund, H. Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 59, 1327-1346 (2002).
18. Lotfi, K. et al. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin. Cancer Res. 5, 2438-2444 (1999).
19. Mansson, E. et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem. Pharmacol. 65, 237-247 (2003).
20. Kantarjian, H.M. et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol. 21, 1167-1173 (2003).
21. Wang, J., Choudhury, D., Chattopadhyaya, J. & Eriksson, S. Stereoisomeric selectivity of human deoxyribonucleoside kinases. Biochemistry 38, 16993-16999 (1999).
22. Kewn, S., Veal, G.J., Hoggard, P.G., Barry, M.G. & Back, D.J. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54, 589-595 (1997).
23. Gourdeau, H. et al. Mechanism of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res. 61, 7217-7224 (2001).
24. Townsley, C.A. et al. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 21, 1524-1529 (2003).
25. Giles, F.J. et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J. Clin. Oncol. 21, 1050-1056 (2003).
26. Doublie, S. Preparation of selenomethionyl proteins for phase determination. Methods Enzymol. 276, 523-530 (1997).
27. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystal. 24, 795-800 (1993).
28. Otwinowski, Z. & Minor, W. Processing of X-ray data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
29. Terwilliger, T.C. Reciprocal-space solvent flattening. Acta Crystallogr. D 55, 1B63-1871 (1999).
30. Jones, T.A., Zhou, J.Y., Cowan, S.W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119 (1991).
31. Brünger, A.T. X-PLOR: A System for X-ray Crystallography and NMR (Yale University Press, New Haven, 1993).
32. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum likelihood method. Acta Crystallogr. D 53, 240-255 (1997).
33. Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50, 157-163 (1994).
34. Perrakis, A., Morris, R. & Lamzin, V.S. Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 6, 458-463 (1999).
35. Agarwal, K.C., Miech, R.P. & Parks, R.E. Jr. Guanylate kinases from human erythrocytes, hog brain, and rat liver. Methods Enzymol. 51, 483-490 (1978).
36. Esnouf, R. An extensively modified version of MOLSCRIPT that includes greatly enhanced coloring capabilities. J. Mol. Graph. 15, 133-138 (1997).
37. Merrit, E.A. & Murphy, M.E.P. Raster3D version 2.0 - a program for photorealistic molecular graphics. Acta Crystallogr. D 50, 869-873 (1994).